medigraphic.com
ISSN 2070-8718 (Print)

2011, Number 1

<< Back Next >>

Rev Cub Gen 2011; 5 (1)

The role of CYP2D6 cytochrome in the pharmacogenetics era

Roblejo BH

Language: Spanish
References: 30
Page:
PDF size: 102.73 Kb.


ABSTRACT

Understanding the molecular basis of drug action or drug toxicity as well as genetic determinants that may influence the response of individuals, allows optimizing their application, in what is called at present personalized medicine. This review focuses on the purposes and potential benefits of pharmacogenetics and discusses the role of polymorphisms of the CYP2D6 enzyme in the metabolism of drugs, since it catalyzes the oxidative biotransformation of nearly 25% of common use drugs.


REFERENCES

  1. BOLETÍN CIME (Centro de Información sobre Medicamentos). Reacciones Adversas a los Medicamentos. [en línea] Mayo 1999. URL disponible en: http://www.garrahan.gov.ar/cime/boletines/vigila.htm

  2. Eichelbaum M, Ingelman-Sundberg M, Evans W.E. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119–137.

  3. Paul E, End-Rodriguez T, Thylen P, Bergman U. Adverse drug reactions a common cause of hospitalization of the elderly. A clinical retrospective study. Lakartidningen. 2008;105:2338–2342.

  4. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007;167:1752– 1759.

  5. Ma K, Woo MH, Mcleod HL. Genetic basis of drug metabolism. Am J Health- Syst Pharm. 2002;59(21):2061-2069.

  6. Nussbaum R.L, McInnes R.R.,.Willard H.F. Farmacogenética y Farmacogenómica. En Thompson & Thompson Genética en Medicina. 7ma. Edición. Madrid: Elsevier, S.L. MASSON; 2008.

  7. Almaguer Mederos LE, Rodríguez Almira Y, González Zaldivar Y, Laffita Mesa J. La farmacogenómica: un acercamiento a una medicina personalizada. Correo Científico Médico de Holguín [en línea] 2003 [fecha de acceso 28 de marzo de 2009];7(3).URL disponible en: http://www.cocmed.sld.cu/no73/n73rev3.htm

  8. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998; 45:525-38.

  9. Danielson P. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561-97.

  10. Sookoian S, Pirola CJ. Farmacogenética/farmacogenómica en la práctica clínica. MEDICINA (Buenos Aires). 2004;64:563-567.

  11. Ingelman-Sundberg M, Sim S. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochemical and Biophysical Research Communications. 2010;396:90–94.

  12. Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Warfarin metabolism and anticoagulant effect: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clinical Therapeutics. 2007 Mar;29(3):427-437.

  13. Takahashi H, Wilkinson GR, Nutescu EA, Takashi M, Ritchie M D, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenetics & Genomics. 2006 Feb;16(2):101-110.

  14. D'ambrosio Rl, D'andrea G, Cafolla A, Faillace F, Margaglione M. A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. Journal of Thrombosis and Haemostasis. 2007 Jan;5(1):191-193.

  15. Gough AC, Smith CA, Howell SM, et al. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. Genomics. 1993;15:430-2.

  16. Kimura S, Umeno M, Skoda RC, et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989;45:889-904.

  17. Eichelbaum M, Baur MP, Dengler HJ, et al. Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. Br J Clin Pharmacol. 1987;23:455-8.

  18. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allelespecific PCR amplification. Lancet. 1990;336:529-32.

  19. Cozza KL, Armstrong SC. The Cytochrome P450 System. Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing; 2001.

  20. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-18.

  21. Shu-Feng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part I. Clin Pharmacokinet. 2009;48(11):689-723.

  22. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284–295.

  23. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, etal. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193–202.

  24. Helena Buzkova´, Kristina Pechandova´, Ondr¡ej Slanar¡ and Frantis¡ek Perlý´k. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct. 2008;26:76–81.

  25. Flores-Pérez J y cols. El apoyo del citocromo P450 (CYP2D6) en el uso de medicamentos antipsicóticos. Acta Pediatr Mex. 2007;28(6):278-284.

  26. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics. 2005;15:151-158.

  27. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med. 2008;28:619-26.

  28. Shu-Feng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part II. Clin Pharmacokinet. 2009;48(12):761-804.

  29. Frueh F.W., Amur S., Mummaneni P., Epstein R.S., Aubert R.E., DeLuca T.M., Verbrugge R.R., Burckart G.J., Lesko L.J. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28:992–998.

  30. Banda Gurrola S, Torres Guevara EJ, Chávez Ramírez HJ. Farmacogenética y farmacogenómica: hacia una medicina personalizada. Rev Fac Med UNAM [en línea] 2010 [fecha de acceso 28 de marzo de 2010]; 53(2).URL disponible en: http://new.medigraphic.com/cgi-bin/contenidoMain.cgi




2020     |     www.medigraphic.com